• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Dabrafenib Mesylate

Dabrafenib Mesylate

Product ID D0005
Cas No. 1195768-06-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $68.30 In stock
25 mg $152.30 In stock
100 mg $362.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195768-06-9

Purity

≥98%

Formula

C23H20F3N5O2S2・CH3SO3H

Formula Wt.

615.67

Chemical Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide;methanesulfonic acid

IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide;methanesulfonic acid

Solubility

soluble in DMSO

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D0005 MSDS PDF

Info Sheet

D0005 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M9646

    Myelin Basic Protein (68-82), guinea pig

    Immunodominant peptide epitope occurring in mul...

    ≥95%
  • E543721

    Ensartinib

    A third-generation ALK inhibitor.

    ≥98%
  • E7668

    Etretinate

    Aromatic retinoid; RAR, RXR agonist.

    ≥98%
  • P1764

    Pep-1 Peptide

    Cell-penetrating peptide, carries large conjuga...

    ≥95%
  • H9618

    Hydroquinone

    Basic phenol skeleton structure found in variou...

    ≥96%
  • A9714

    AZD-1152-HQPA

    AurKA/B inhibitor.

    ≥98%
  • D183738

    19-O-Demethyl rapamycin

    Fermentation impurity

    ≥97%
  • S7618

    StemRegenin 1 Hydrochloride

    AhR antagonist.

    ≥98%
  • H1648

    Hemorphin-7

    Endogenous opioid peptide derived from the β-c...

    ≥95%
  • I4000

    Ikarugamycin

    Protein translation inhibitor.

    ≥98%
  • V3253

    Vinblastine Sulfate

    Vinca alkaloid found in Catharanthus; microtubu...

    ≥96%
  • T0110

    Taxane Standard Mixture

    Mixture of taxanes.

    ≥98%
  • B8274

    Buspirone Hydrochloride

    Azapirone; α1-adrenergic and 5-HT1A partial ag...

    ≥98%
  • Y1000

    Y27632 Dihydrochloride

    ROCK inhibitor.

    ≥99%
  • C0253

    Candesartan

    AT1 inhibitor.

    ≥98%
  • C600000

    CP 55940

    Non-selective CB receptor agonist.

    ≥97%
  • P2516

    S-(N-Phenylbutylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant.

    ≥98%
  • M400005

    MK-5108 Hydrochloride

    Aurora kinase A inhibitor.

    ≥98%
  • S0033

    Saikosaponin B2

    Saponin found in Bupleurum, Heteromorpha, and S...

    ≥98%
  • O7332

    OSI-027

    mTOR inhibitor.

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only